date,title,source
Oct-30-18,"Audentes Therapeutics to Release Third Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, November 6, 2018",PR Newswire
Nov-05-18,Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman,PR Newswire
Nov-06-18,Audentes Therapeutics: 3Q Earnings Snapshot,Associated Press
Nov-06-18,Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update,PR Newswire
Nov-07-18,Audentes Therapeutics to Participate in Upcoming Investor Conferences,PR Newswire
Nov-09-18,"Recent Analysis Shows Audentes Therapeutics, Endocyte, Bluerock Residential Growth REIT, Air Products and Chemicals, BWX Technologies, and Modine Manufacturing Market Influences  Renewed Outlook, Key Drivers of Growth",GlobeNewswire
Nov-12-18,These Biopharmas Could Cure Genetic Diseases  At $5 Million Apiece,Investor's Business Daily
Nov-16-18,Edited Transcript of BOLD earnings conference call or presentation 6-Nov-18 9:30pm GMT,Thomson Reuters StreetEvents
Dec-07-18,Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),PR Newswire
Dec-13-18,"Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay",American City Business Journals
Dec-18-18,"Is Audentes Therapeutics, Inc. (BOLD) Going to Burn These Hedge Funds?",Insider Monkey
Dec-21-18,"Need To Know: Audentes Therapeutics, Inc. (NASDAQ:BOLD) Insiders Have Been Selling Shares",Simply Wall St.
Jan-02-19,Audentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference,PR Newswire
Jan-03-19,Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial Officer,PR Newswire
Jan-04-19,Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),PR Newswire
Jan-07-19,Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key Priorities,PR Newswire
Jan-31-19,Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT Designation,PR Newswire
Feb-05-19,Mizuho's 9 Best Biotech Stocks to Buy for 2019,Kiplinger
Feb-08-19,Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),PR Newswire
Feb-13-19,"Report: Developing Opportunities within Dunkin' Brands Group, Murphy Oil, NII, Audentes Therapeutics, RealNetworks, and MDC Partners  Future Expectations, Projections Moving into 2019",GlobeNewswire
Feb-20-19,Audentes Therapeutics to Participate in Upcoming Investor Conferences,PR Newswire
Feb-21-19,"Audentes Therapeutics to Release Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update on Wednesday, February 27, 2019",PR Newswire
Feb-26-19,Biotech ETFs Jump on Roche-Spark Deal,Zacks
Feb-27-19,Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update,PR Newswire
Feb-28-19,"Audentes Therapeutics Recognizes Rare Disease Day by Launching ""Be Bold for Courageous Patients"" Program to Support Patients Living with Rare Diseases",PR Newswire
Mar-07-19,Audentes Therapeutics (BOLD) Upgraded to Buy: Here's What You Should Know,Zacks
Mar-08-19,Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),PR Newswire
Mar-08-19,"Introducing Audentes Therapeutics (NASDAQ:BOLD), The Stock That Dropped 10% In The Last Year",Simply Wall St.
Mar-18-19,Spark Unlikely To Get A Better Bid  But These Stocks Could Be In Play,Investor's Business Daily
Mar-29-19,"Factors of Influence in 2019, Key Indicators and Opportunity within Nutanix, Steel Dynamics, Audentes Therapeutics, Comfort Systems, LHC Group, and Cambrex  New Research Emphasizes Economic Growth",GlobeNewswire
Apr-01-19,Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial Officer,PR Newswire
Apr-05-19,Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),PR Newswire
Apr-08-19,4 Gene Therapy Players Likely to Become Buyout Targets in 2019,Zacks
Apr-08-19,Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy,PR Newswire
Apr-15-19,"Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy",PR Newswire
